---
figid: PMC3962044__nihms-563066-f0004
figtitle: IAP antagonists promote bone metastasis via activation of alternative NFKB
  pathway
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC3962044
filename: nihms-563066-f0004.jpg
figlink: /pmc/articles/PMC3962044/figure/F4/
number: F4
caption: IAP antagonists promote bone metastasis via activation of alternative NF-κB
  pathway. The presence of IAP antagonists enhances the degradation of cIAP1/2, stabilizing
  more NIK, thereby increasing more osteoclastogenic signaling through p52/RelB. Elevated
  numbers of osteoclasts provide a favorable microenvironment for bone metastasis
  through release of tumor growth factors from bone matrix and a positive feedback
  loop from RANKL-secreting osteoblasts. Osteoclast inhibiting agents such as bisphosphonates
  can interrupt this vicious cycle, reducing the osteolytic and pro-tumor effects
  of IAP antagonists
papertitle: 'Anti-cancer IAP antagonists promote bone metastasis: a cautionary tale.'
reftext: Chang Yang, et al. J Bone Miner Metab. ;31(5):496-506.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9569861
figid_alias: PMC3962044__F4
figtype: Figure
redirect_from: /figures/PMC3962044__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3962044__nihms-563066-f0004.html
  '@type': Dataset
  description: IAP antagonists promote bone metastasis via activation of alternative
    NF-κB pathway. The presence of IAP antagonists enhances the degradation of cIAP1/2,
    stabilizing more NIK, thereby increasing more osteoclastogenic signaling through
    p52/RelB. Elevated numbers of osteoclasts provide a favorable microenvironment
    for bone metastasis through release of tumor growth factors from bone matrix and
    a positive feedback loop from RANKL-secreting osteoblasts. Osteoclast inhibiting
    agents such as bisphosphonates can interrupt this vicious cycle, reducing the
    osteolytic and pro-tumor effects of IAP antagonists
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TNFSF11
  - TNFRSF11A
  - ALPI
  - ALPP
  - CD47
  - IAPP
  - MAGT1
  - BIRC2
  - BIRC3
  - MAP3K14
  - MAP4K4
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - FKBP4
  - GTF2H4
  - NFKB2
  - PMPCB
  - PSIP1
  - H3P42
  - RELB
---
